Aperio Group LLC reduced its stake in shares of Mednax, Inc (NYSE:MD) by 5.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,676 shares of the company’s stock after selling 1,329 shares during the period. Aperio Group LLC’s holdings in Mednax were worth $1,429,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of MD. Louisiana State Employees Retirement System increased its stake in shares of Mednax by 2.5% in the second quarter. Louisiana State Employees Retirement System now owns 24,300 shares of the company’s stock valued at $1,467,000 after buying an additional 600 shares in the last quarter. LS Investment Advisors LLC increased its stake in shares of Mednax by 15.6% in the second quarter. LS Investment Advisors LLC now owns 6,981 shares of the company’s stock valued at $421,000 after buying an additional 940 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of Mednax by 4.6% in the second quarter. Oregon Public Employees Retirement Fund now owns 34,030 shares of the company’s stock valued at $2,054,000 after buying an additional 1,485 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Mednax by 527.2% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock valued at $919,000 after buying an additional 12,800 shares in the last quarter. Finally, Fenimore Asset Management Inc. increased its stake in shares of Mednax by 1.8% in the second quarter. Fenimore Asset Management Inc. now owns 873,960 shares of the company’s stock valued at $52,761,000 after buying an additional 15,080 shares in the last quarter.

Mednax, Inc (MD) traded up 1.57% during trading on Friday, reaching $42.76. The company had a trading volume of 917,314 shares. The stock has a 50 day moving average price of $54.16 and a 200 day moving average price of $61.44. Mednax, Inc has a 12 month low of $41.52 and a 12 month high of $72.13. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of 13.62 and a beta of 0.40.

Mednax (NYSE:MD) last issued its earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. Mednax’s revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.03 earnings per share. On average, equities research analysts predict that Mednax, Inc will post $3.31 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Aperio Group LLC Sells 1,329 Shares of Mednax, Inc (MD)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/13/aperio-group-llc-sells-1329-shares-of-mednax-inc-md.html.

Several analysts have recently issued reports on the company. BidaskClub downgraded Mednax from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Mizuho reiterated a “neutral” rating and set a $48.00 target price (down from $62.00) on shares of Mednax in a research report on Tuesday, August 1st. Jefferies Group LLC set a $46.00 target price on Mednax and gave the stock a “hold” rating in a research report on Sunday, July 30th. Stephens upgraded Mednax from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd. Finally, ValuEngine downgraded Mednax from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $64.00.

In related news, insider Joseph M. Calabro sold 23,327 shares of Mednax stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the sale, the insider now owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total value of $113,355.33. Following the sale, the director now directly owns 18,072 shares of the company’s stock, valued at approximately $1,040,405.04. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.